Loan book momentum to take centre stage as IREDA reports Q1 results

Loan book growth and interest income trajectory are the north stars for IREDA investors. The company's core mandate—financing renewable energy projects toward India's 500 GW target by 2030—means loan disbursement traction directly drives revenue. FY26 delivered strong fundamentals: interest income up 24% to ₹8,180 Cr, loan book up 22% to ₹93,069 Cr, and loan disbursements up 16% to ₹34,946 Cr. Q1 FY27 will show whether this momentum survives Q1 (historically seasonal), and critically, whether profit margins stabilise after Q4's 15.8% QoQ decline.

Strong Q1 = continued loan disbursement traction and NII expansion despite margin squeezed. Loan book crosses ₹97,500 Cr; interest income stays on the 23–24% growth rails; profit stays above ₹350 Cr despite Q4's dip. Weak Q1 = disbursements cool, loan book growth rate slips below 5% QoQ, or NPA stress emerges from prior-period slippages. Profit below ₹300 Cr signals margin compression beyond seasonal norm; guidance miss on loan sanctions (FY26 was only +9% vs 16% disbursement growth) hints at pipeline contraction.

FY26 was solid: revenue +23%, loan book +22%, disbursements +16%. Full-year FY27 guidance remains unverified against actuals (not disclosed in our data), so Q1 operates in a vacuum. That said, the trajectory is intact. India's renewable energy capex push, driven by the 500 GW target and supporting schemes, means pipeline visibility for IREDA is high. The caution: Q4 FY26 profit declined 15.8% QoQ despite revenue growth—a sign that interest-rate regime, cost inflation, and potential credit provisions are eating into margins. Q1 will test whether this is structural or seasonal.

IREDA is a bellwether for India's green-energy financing machine. FY26 proved the business model works: 23% revenue growth, 22% loan book expansion, and solid disbursement momentum. Q4 FY26 profit weakness and the Gensol fraud shadow the picture. On Aug 3, the Board will approve Q1 FY27 results. Investors will parse three things: (1) interest income growth—hold above 20% YoY for confidence; (2) loan book trajectory—any slowdown below 5% QoQ or 20% YoY is a red flag; (3) Gensol exposure and provisioning—a silent killer if material. The stock is oversold technically (RSI 24.5) and trades 24% below ATH, but valuation won't rerate without proof that margins are stabilising. Result day will answer that.